Covis Pharma

Covis Pharma built its model around acquiring and commercialising established, off-patent branded medicines that larger pharmaceutical companies no longer prioritise, giving those products renewed focus and commercial investment. Founded in 2011 and headquartered in Zug, Switzerland, the company operates internationally with a significant commercial presence across Europe and North America.

The portfolio centres on specialty and hospital medicines, with particular depth in cardiovascular, respiratory, and women's health therapy areas. Key marketed products include treatments for heart failure, hypertension, and related cardiovascular conditions, alongside respiratory medicines and products addressing acute obstetric and gynaecological needs. Rather than pursuing early-stage drug discovery, Covis focuses on lifecycle management and ensuring continued patient access to medicines that retain clinical relevance.

Covis operates through direct commercial infrastructure in multiple European markets and partners with distributors and co-promotion arrangements where its own footprint does not reach. The company has grown substantially through a series of portfolio acquisitions from major pharmaceutical groups, adding assets that benefit from dedicated commercial attention rather than competing for resources within large multinational pipelines.

The business is privately held and backed by Apollo Global Management, which has supported its acquisition-led growth strategy. This structure allows Covis to move with relative speed on asset deals and to take a long-term view on branded generics and mature specialty products that still address unmet patient needs in their therapeutic categories.

Further information is available at covispharma.com.